GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taisho Pharmaceutical Holdings Co Ltd (TSE:4581) » Definitions » Sloan Ratio %

Taisho Pharmaceutical Holdings Co (TSE:4581) Sloan Ratio % : 0.00% (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Taisho Pharmaceutical Holdings Co Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Taisho Pharmaceutical Holdings Co's Sloan Ratio for the quarter that ended in Dec. 2023 was 0.00%.

As of Dec. 2023, Taisho Pharmaceutical Holdings Co has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Taisho Pharmaceutical Holdings Co Sloan Ratio % Historical Data

The historical data trend for Taisho Pharmaceutical Holdings Co's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taisho Pharmaceutical Holdings Co Sloan Ratio % Chart

Taisho Pharmaceutical Holdings Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.46 9.86 -3.05 -0.94 0.55

Taisho Pharmaceutical Holdings Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Taisho Pharmaceutical Holdings Co's Sloan Ratio %

For the Drug Manufacturers - Specialty & Generic subindustry, Taisho Pharmaceutical Holdings Co's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taisho Pharmaceutical Holdings Co's Sloan Ratio % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taisho Pharmaceutical Holdings Co's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Taisho Pharmaceutical Holdings Co's Sloan Ratio % falls into.



Taisho Pharmaceutical Holdings Co Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Taisho Pharmaceutical Holdings Co's Sloan Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Sloan Ratio=(Net Income (A: Mar. 2023 )-Cash Flow from Operations (A: Mar. 2023 )
-Cash Flow from Investing (A: Mar. 2023 ))/Total Assets (A: Mar. 2023 )
=(18997-40972
--27130)/941490
=0.55%

Taisho Pharmaceutical Holdings Co's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(8421-0
-0)/1005463
=0.84%

Taisho Pharmaceutical Holdings Co's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -1902 (Mar. 2023 ) + 4363 (Jun. 2023 ) + 3087 (Sep. 2023 ) + 2873 (Dec. 2023 ) = 円8,421 Mil.
Taisho Pharmaceutical Holdings Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was 0 (Mar. 2023 ) + 0 (Jun. 2023 ) + 0 (Sep. 2023 ) + 0 (Dec. 2023 ) = 円0 Mil.
Taisho Pharmaceutical Holdings Co's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was 0 (Mar. 2023 ) + 0 (Jun. 2023 ) + 0 (Sep. 2023 ) + 0 (Dec. 2023 ) = 円0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Taisho Pharmaceutical Holdings Co  (TSE:4581) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Taisho Pharmaceutical Holdings Co has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Taisho Pharmaceutical Holdings Co Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Taisho Pharmaceutical Holdings Co's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Taisho Pharmaceutical Holdings Co (TSE:4581) Business Description

Traded in Other Exchanges
Address
3-24-1 Takada, Toshima-ku, Tokyo, JPN, 170-8655
Taisho Pharmaceutical Holding Co Ltd is a specialty and generic drug manufacturing company. The company maintains two operational segments, Self-Medication and Prescription Pharmaceuticals. The vast majority of Taisho's revenue is derived from its Self-Medication segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The vast majority of sales are generated by sales to external customers in Japan.

Taisho Pharmaceutical Holdings Co (TSE:4581) Headlines

No Headlines